Skip to main content
. 2023 Jul 4;24(7):193. doi: 10.31083/j.rcm2407193

Table 1.

Characteristics of the eligible studies included in the systematic review.

First author, year Country Setting POI group Control group Follow up time Number of events Number of events
Sample size Sample size (Incidence %) in POI group (Incidence %) in Control group
Baba et al. 2010 [21] Japan Jichi Medical School population-based prospective study N = 237 N = 2171 Mean of 10.8 y Stroke: 10 (4.2) Stroke: 76 (3.5)
Choi et al. 2005 [22] Korea The Korean Elderly Pharmacoepidemiologic population-based Cohort study N = 84 N = 2555 27,936 person-y (5 y) Stroke: 3 (3.5) Stroke: 87 (3.4)
Cooper et al. 1998 [23] USA National Health and Examination Survey Epidemiologic Follow-up study N = 115 N = 1475 Mean of 4 y Death due to any cardiovascular events: 9 (7.83) Death due to any cardiovascular events: 71 (4.8)
Dam et al. 2019 [24] 10 European countries EPIC-CVD, a case–cohort study, which includes data from 23 centres from 10 European countries N = NM N = NM Median of 11 y Coronary heart disease: 364 (43.8%) Coronary heart disease: 1563 (45.4%)
Gallagher et al. 2011 [25] China Shanghai population-based Cohort study N = 16,029 N = 450,359 Median of 10 y Coronary heart disease: 7 (0.04) Coronary heart disease: 175 (0.04)
Stroke: 43 (0.27) Stroke: 986 (0.22)
Hong et al. 2007 [26] South Korean Kangwha population-based Cohort study N = 198 N = 948 Median of 15.8 y Death due to any cardiovascular events: 27 Death due to any cardiovascular events: 101
Honigberg et al. 2021 [27] UK UK Biobank population-based Cohort study N = 5201 N = 86,557 Median of 11.1 y PH: 38 (0.73%) PH: NM
HR: 2.36, 95% CI: 1.49–3.73
Honigberg et al. 2019 [28] UK UK Biobank population-based Cohort study N = 5548 N = 138,712 Median of 7 y Coronary heart disease: 124 (2.24) Coronary heart disease: 1646 (1.19)
Heart failure: 50 (0.9) Heart failure: 722 (0.5)
Stroke: 35 (0.6) Stroke: 584 (0.4)
HTN: 301 (5.4) HTN: 5007 (3.6)
Heart valve disease: 44 (0.7) Heart valve disease: 604 (0.4)
Honigberg et al. 2021 [29] UK UK Biobank population-based Cohort study N = 1305 N = 18,301 Median of 7-13.1 y Coronary heart disease: 162 (12.4) Coronary heart disease 1568 (8.5)
Hu et al. 1999 [30] USA Nurses’ Health study, population-based Cohort study N = NM N = NM Median of 18 y Coronary heart disease: 18 Coronary heart disease: 375
Stroke: 4 Stroke: 182
Ley et al. 2017 [31] USA Nurses’ Health study, population-based Cohort study N = NM N = NM 1,467,987 person-y Coronary heart disease: 177 Coronary heart disease: 1306
Stroke: 163 Stroke: 1239
Li et al. 2013 [32] USA Black Women’s Health study, population-based Cohort study N = 586 N = 4747 Median of 13 y Death due to any cardiovascular events: 15 Death due to any cardiovascular events: 70
Løkkegaard et al. 2006 [33] Denmark Danish Nurse N = 380 N = 8186 Median of 5 y Coronary heart disease: 7 Coronary heart disease: 3
population-based Cohort study HR: 2.1, 95% CI: 1.3–3.5
Ossewaarde et al. 2005 [34] Netherlands breast cancer screening cohort, population-based Cohort study N = 454 N = 5753 Median of 17 y Death due to any cardiovascular events: 50 Death due to any cardiovascular events: 445
van der Schouw et al. 1996 [35] Netherlands DOM project, population-based Cohort study N = 459 N = 5741 Median of 20 y Death due to any cardiovascular events: 43 Death due to any cardiovascular events: 391
Welten et al. 2021 [36] Netherlands (European Prospective Investigation into Cancer N = 2407 N = 5353 Median of 15 y Stroke: 121 Stroke: 310
and Nutrition–Netherlands) population-based Cohort study

N, number; NM, not mentioned; y, year. HR, hazard ratio; CI, confidence interval; POI, premature ovarian insufficiency; EPIC-CVD, European Prospective Investigation into Cancer and Nutrition (EPIC) study; PH, pulmonary hypertension; HTN, hypertension; DOM, Diacnostisch Onderzoek (investigation Mammacarcinoom).